Anthony Hooper
MANNKINDAbout Anthony Hooper
Anthony Hooper, age 70, has served on MannKind’s Board since January 2020. He is Chair of the Compensation Committee and a member of the Audit Committee, and is deemed independent under Nasdaq rules. He previously held senior commercial leadership roles at Amgen and Bristol‑Myers Squibb and holds law and MBA degrees from the University of South Africa. The Board cites his extensive drug commercialization experience and service on other boards as core credentials supporting his effectiveness.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Amgen Inc. | Executive Vice President, Global Commercial Operations | Oct 2011–Aug 2018 | Led global commercialization; Board cites extensive commercialization experience as a qualification. |
| Bristol-Myers Squibb (BMS) | Senior Vice President, Global Commercial Operations; President of pharma business in Americas, Japan, Intercontinental | 15+ years (dates not fully disclosed) | Senior leadership across major geographies; deep global commercial expertise. |
| Wyeth Laboratories | Assistant Vice President, Global Marketing | Not disclosed | Global marketing leadership. |
| Lederle International | Led international marketing group | Not disclosed | International marketing leadership. |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BeiGene, Ltd. (public) | Director | Not disclosed | Not disclosed. |
| Amplity Health (private) | Director | Not disclosed | Not disclosed. |
Board Governance
- Independence: The Board determined all directors except Messrs. Castagna and Binder are independent; Hooper is independent.
- Committee assignments: Compensation Committee (Chair); Audit Committee (Member); both committees comprised of independent directors per Nasdaq rules.
- Attendance and engagement: The Board met nine times in 2024; each director attended at least 75% of Board and committee meetings; independent directors hold regular executive sessions.
- Committee activity: Compensation Committee met five times in 2024; Audit Committee met eight times in 2024.
- Committee scope: Compensation oversees executive pay, succession planning, director compensation, and benefit plan administration; Audit oversees financial reporting, auditor independence, internal controls, risk (including cybersecurity), compliance, and related‑party approvals.
- Board leadership structure: Chair of the Board is Dr. Shannon; CEO and Chair roles are separated to reinforce independent oversight.
Fixed Compensation
| Component (Program) | Amount | Notes |
|---|---|---|
| Annual cash retainer | $50,000 | Standard non‑employee director retainer; directors may elect stock in lieu of cash. |
| Compensation Committee Chair fee | $20,000 | Committee chair fee. |
| Audit Committee member fee | $10,000 | Committee member fee. |
| Meeting fees | $0 | No meeting fees; only annual and committee fees. |
| Cash fees actually paid (2024) | $80,000 | As reported for Hooper. |
Performance Compensation
| Equity Element | Grant/Value | Vesting/Delivery | Performance Metrics |
|---|---|---|---|
| Annual RSU (standard program) | Formula: $250,000 / stock price used for employee awards (not less than last close) | Vests immediately; share delivery deferred until separation from Board service | None disclosed for directors (time‑based immediate vesting). |
| 2024 RSU to Hooper (grant‑date fair value) | $155,959 | Vested immediately; deferred delivery until separation; no unvested RSUs outstanding at year‑end | None disclosed for directors; no option grants to Hooper in 2024. |
The Compensation Committee Report is signed by Hooper as Chair, indicating active leadership and oversight of executive compensation processes.
Other Directorships & Interlocks
| Connection Type | Detail |
|---|---|
| Current public board | BeiGene, Ltd. (Director). |
| Other board | Amplity Health (Director). |
| Interlocks/reciprocal service | None disclosed; Compensation Committee members have never been MNKD officers; no executive compensation committee interlocks in 2024. |
| Related‑party transactions | None in 2024 per Related‑Person Transactions Policy and disclosure. |
Expertise & Qualifications
- Extensive global pharma commercialization leadership at Amgen and BMS; prior senior marketing roles at Wyeth and Lederle International.
- Education: Law and MBA degrees from the University of South Africa.
- Board rationale: Business acumen, commercialization expertise, and other public board service cited as qualifications.
Equity Ownership
| Item | Amount | Notes |
|---|---|---|
| Beneficial ownership (shares) | 176,153 | As of March 20, 2025; “<1%” of shares outstanding. |
| Ownership percent | <1% | Based on 303,855,633 shares outstanding. |
| Options outstanding | None | Hooper had no options outstanding as of Dec 31, 2024. |
| Vested RSUs awaiting delivery | 329,726 | Vested RSUs to be delivered upon separation from Board service. |
| Unvested RSUs | 0 | As of Dec 31, 2024. |
| Hedging/pledging | Prohibited | Company insider trading policy bans pledging, hedging, shorts, margin, and options on MNKD stock. |
| Ownership guidelines | 3x annual retainer / current stock price | All non‑employee directors were in compliance as of Dec 31, 2024. |
Governance Assessment
- Strengths: Independent status; Chair of Compensation Committee with regular meeting cadence; member of Audit Committee; no related‑party transactions in 2024; robust insider trading policy prohibiting hedging/pledging; compliance with director stock ownership guidelines; clear separation of Chair and CEO roles.
- Alignment: Equity compensation with deferred share delivery until separation enhances long‑term alignment; no meeting fees; committee fee structure transparent and modest.
- Attendance/engagement: Board met nine times; each director attended ≥75% of Board/committee meetings; independent directors meet in executive session.
- Potential risks/RED FLAGS: None identified in disclosures—no director option grants in 2024 (reduces repricing risk), no Section 16 delinquency noted for Hooper, and no related‑party transactions reported. Continued service on an external biopharma board (BeiGene) warrants routine monitoring for any future conflicts, but none are disclosed.